Tarsa Therapeutics
Manufacturing · Pennsylvania, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
1628 John F Kennedy Blvd Ste 1400, Phila...Phone Number
(267) 273-7940Website
www.tarsatherapeutics.comRevenue
$5.5 MillionIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About Tarsa Therapeutics
Tarsa Therapeutics specializes in developing innovative treatments for postmenopausal osteoporosis, notably their product TBRIA, a novel oral formulation of calcitonin. TBRIA is designed for women more than five years post-menopause when other treatments are unsuitable, and it has shown positive safety and efficacy in clinical trials. The product aims to be the first approved oral calcitonin, leveraging a natural hormone with a proven history of safety. Rights to TBRIA have been acquired by R-Pharm JSC, which will oversee its further clinical development and regulatory processes.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Tarsa Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if Tarsa Therapeutics had a recent Job posting/layoffs
Funding: Get notified immidiatlly once Tarsa Therapeutics has new funding data
Tarsa Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on Tarsa Therapeutics recently announced quarterly report
Product Launch: Get notified when Tarsa Therapeutics launches new products
Congratulate Masked Content for being promoted to Masked Content at Tarsa Therapeutics
Check if Tarsa Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Check out if Tarsa Therapeutics is spiking on competitors!
Recommended Actions
Find VP level buyers at Tarsa Therapeutics
Find 2 more new buyers
Compare Similar Companies to Tarsa Therapeutics
Compare insights from companies similar to Tarsa Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Tarsa Therapeutics
$5.5M
11-50
Private
$91.9M
2009
N/A
Company Profile Activity
Activity Insights
Tarsa Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Tarsa Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Tarsa Therapeutics.
Tarsa Therapeutics financials insights
Gather financial insights about Tarsa Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2010
Series A
$24M
2011
Unspecified
$24.5M
2012
Series B
$28M
2014
Debt
$10M
2016
Multiple Rounds
$4.9M
2017
Debt
$549K
Tarsa Therapeutics Tech Stack
A closer look at the technologies used by Tarsa Therapeutics
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Tarsa Therapeutics
Sign Up For FreeTo access detailed company insights
Tarsa Therapeutics specializes in developing innovative treatments for postmenopausal osteoporosis, notably their product TBRIA, a novel oral formulation of calcitonin. TBRIA is designed for women more than five years post-menopause when other treatments are unsuitable, and it has shown positive safety and efficacy in clinical trials. The product a... Read More
